Cardiol Therapeutics Inc.

Toronto Stock Exchange:CRDL.TO

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

Location

Canada

Market Cap

USD 102.25 M

Share Price

USD 1.24

Avg Daily Volume

87,950

Change (1 day)

-5.23%

Change (1 year)

-33.83%

Change (YTD)

-3.77%

Cardiol Therapeutics Inc. Revenue for the year ending December 31, 2024: USD 0.00

Cardiol Therapeutics Inc. Revenue is USD 0.00 for the year ending December 31, 2024. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Cardiol Therapeutics Inc. Revenue for the year ending December 31, 2023 was USD 0.00.
Cardiol Therapeutics Inc. Revenue for the year ending December 31, 2022 was USD 0.00, a -100.00% change year over year.
Cardiol Therapeutics Inc. Revenue for the year ending December 31, 2021 was USD 62.27 K.
Cardiol Therapeutics Inc. Revenue for the year ending December 31, 2020 was USD 0.00.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

Toronto Stock Exchange: CRDL.TO

Cardiol Therapeutics Inc.

CEO	Mr. David G. Elsley MBA
IPO Date	Dec. 20, 2018
Location	Canada
Headquarters	2265 Upper Middle Road East
Employees	18
Sector	🏥 Health Care
Industries Clinical Trials

Description

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.